Sandoz, Biolab join Brazil’s growing semaglutide market
Amid growing competition in the weight-loss drug market, drugmakers Sandoz and Biolab are entering the race for a share of the semaglutide market—the active ingredient in diabetes and weight-loss drugs such as Ozempic—which generated R$5.6 billion in …